For Immediate Release
Chicago, IL – October 2, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Mylan Inc. (MYL - Analyst Report), Sanofi (SNY - Analyst Report), Novartis (NVS - Analyst Report), Dr. Reddy's Laboratories Ltd. (RDY - Analyst Report) and Teva Pharmaceutical Industries Ltd. (TEVA - Analyst Report).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Monday’s Analyst Blog:
More Generic Launches at Mylan
Mylan Pharmaceuticals Inc., a subsidiary of Mylan Inc. (MYL - Analyst Report), recently announced that it has launched its generic version of Sanofi's (SNY - Analyst Report) Avapro (irbesartan) 75 mg, 150 mg and 300 mg tablets after receiving final approval from the US Food and Drug Administration (FDA).
Avapro is used for hypertension and type II diabetic nephropathy. According to IMS Health, Avapro (75 mg, 150 mg and 300 mg tablets), generated US revenues of approximately $400.7 million for the 12 months ending June 30, 2012.
Meanwhile, Mylan has also launched its generic version of Sanofi’s Avalide (150/12.5mg and 300/12.5 mg), a fixed-dose combination of Avapro and a diuretic (hydrochlorothiazide) for initial use in patients with hypertension, who might need several drugs control their blood pressure. According to IMS Health, Avalide (150/12.5mg and 300/12.5 mg tablets), generated US revenues of approximately $117.4 million for the 12 months ending June 30, 2012.
Apart from Mylan, several other generic manufacturers including Sandoz, the generic division of Novartis (NVS - Analyst Report) and Dr. Reddy's Laboratories Ltd. (RDY - Analyst Report) have received approval for their generic versions of Avapro and Avalide. We note that Teva Pharmaceutical Industries Ltd. (TEVA - Analyst Report) was the first to receive approval for Avapro and Avalide in April 2012 and enjoyed a 180-day period of marketing exclusivity.
As of September 28, 2012, Mylan had 168 ANDAs pending FDA clearance, targeting $79 billion in branded sales annually. Mylan believes that about 33 of these pending abbreviated new drug applications (ANDAs) are first-to-file opportunities, representing approximately $20.7 billion in branded sales. The revenue figures are as per IMS Health for the 12 months ending June 30, 2012.
We are encouraged by Mylan’s geographic reach and product depth along with a robust generic product pipeline. However, we remain concerned about the company’s lackluster performance in the Europe, Middle East and Africa (EMEA) region.
Additionally, with most large branded drugs due to lose patent exclusivity within the 2017-2018 period, we have little visibility on the growth prospects of generic companies like Mylan beyond that timeframe.
Thus, we prefer to remain on the sidelines and have a Neutral recommendation on Mylan. The stock carries a Zacks #2 Rank (Buy rating) in the short run.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339